VKTX
Viking Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VKTX
Viking Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing therapies for the treatment of metabolic and endocrine disorders
Pharmaceutical
09/24/2012
04/29/2015
NASDAQ Stock Exchange
36
12-31
Common stock
9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121
--
Viking Therapeutics, Inc., was incorporated in Delaware on September 24, 2012. The company is a clinical-stage biopharmaceutical company dedicated to the development of new, first class or best class therapies for metabolic and endocrine disorders. The company has global exclusive rights to licence-based ligand small molecule combinations in five drug candidates in clinical trials or preclinical studies. The company's leading clinical program is VK 0612, an oral drug for the treatment of diabetes that has entered phase 2 b clinical trials as one of the world's largest health challenges for type 2, and it ranks first among the same drugs. The Company's second clinical program, vk 5211, delivers oral drug candidates into Phase 2 clinical trials for the treatment of uncontrolled muscle mass loss cancer cachexia characterized by a complex disease. VK 5211 is a non-steroidal selective androgen receptor modulator, or SARM.
Earnings Call
Q2/2025
Estimate EPS-0.44
Actual EPS-0.58
Estimate Revenue--
Actual Revenue0
Viking Therapeutics' Q2 2025 Earnings Call: Unpacking Key Contradictions in Phase III Study Strategy
Jul 23,2025 09:54
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.67
Actual EPS-0.81
Estimate Revenue--
Actual Revenue0
Viking Therapeutics' Q3 2025 Earnings Call: Shifting Narratives on Oral Formulation, Dose Ranges, and Phase 3 Timelines Spark Investor Scrutiny
Oct 22,2025 08:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VKTX has released its 2025 Q3 earnings. EPS was reported at -0.81, versus the expected -0.67, missing expectations. The chart below visualizes how VKTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
